.jpg)
2019
Shanghai, China, January 23, 2019-- Shanghai HaiHe Biopharma Co., Ltd. (hereinafter referred to as “HaiHe Biopharma”) announced today ,that the company has accomplished the first subject enrollment developed by HaiHe Biopharma the of fthe pivotal phase IIb clinical trial of Thymic CancerFor class 1 innovative drug Lucitanib.
The Chief Physician Prof. Fang Wentao of the Dept. of Thoracic Surgery of Shanghai Chest Hospital acts as the PI.The phase IIb clinical trial of Lucitanib AL3810-202 is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Lucitanib AL3810 in the treatment of patients with advanced recurrent or metastatic Thymic Cancer.
Lucitanib (Code: AL3810) is a three-target oral small molecule kinase inhibitor targeting FGFR1–3, VEGFR1–3 and PDGFRα/β, which is jointly studied by Shanghai Institute of Materia Medica, Chinese Academy of Sciences and its partners. HaiHe Biopharma is responsible for the clinical development, production and commercialization of the drug in China. Preclinical studies have shown that the compound Lucitanib has a strong antitumor activity in vitro and in various animal tumor models. Clinical studies conducted in Europe have shown itsefficacy on alignant tumors including breast cancer and NSCLC etc. with manageable safety.
Haihe Biopharma is an innovation-driven biotechnology company in China focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs. Haihe brings life-saving therapies to cancer patients worldwide. It also has a research and management team with a global perspective, and is proactively mapping out the international development of innovative drugs. The Company currently has thirteen key drug candidates. As of today, Haihe Biopharma has received 21 IND or clinical trial approvals in four countries and regions.
